Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 9/2023

02.08.2023 | Episodic Migraine (S Parikh, Section Editor)

A Brief Review of Gepants

verfasst von: Diana Li, Jessica Abreu, Stewart J. Tepper

Erschienen in: Current Pain and Headache Reports | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Gepants are small molecules that antagonize calcitonin gene-related peptide (CGRP) receptors. Due to their favorable side effect profile and versatility in treating headaches acutely and preventively, gepants are preferred over triptans. We will cover the indications for the four FDA-approved gepants in adults: rimegepant, atogepant, ubrogepant, and zavegepant. This review will illustrate how gepants will continue to revolutionize the acute and preventive treatment of headaches.

Recent Findings

Gepants are now available in oral tablet, dissolving tablet, and intra-nasal spray formulations. Recent studies have shown promising utility in treating the pre-headache or prodromal phase. They have favorable tolerability, no evidence for association with medication overuse, and remain a safer alternative in those who have cerebrovascular risk factors. Additional research is needed to explore occurrence of Raynaud’s phenomenon in participants treated with gepants, as it has been associated with CGRP monoclonal antibodies, but are not extensively studied in gepants.

Summary

Gepants are expected to play a significant role in the next generation of migraine treatments.
Literatur
1.
Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34.PubMedPubMedCentralCrossRef
2.
Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–8.PubMedCrossRef
3.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5)343–349. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46(9):1334–1343.
4.
Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46(9):1334–1343.
5.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.PubMedCrossRef
6.
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1155–283.CrossRef
7.
Schwedt TJ, Buse DC, Argott CE, Reed ML, Fanning KM, Hussar CR, Adams AM, Lipton RB. Medication overuse and headache burden: results from the CaMEO study. Neurology: Clinical Practice. 2021;11(3):216–226.
8.
Sakurada T, Grevés PL, Terenius L. Fragmentation of calcitonin gene-related peptide and substance P in the rat central nervous system. Neurochem Int. 1991;19(3):341–7.CrossRef
9.
Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313(5997):54–6.PubMedCrossRef
10.
Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6.PubMedCrossRef
11.
Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.PubMedCrossRef
12.
Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–86.PubMedCrossRef
13.
Guo S, Vollesen ALH, Olesen J, Ashina M. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain. 2016;57(12):2773–81.CrossRef
14.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–7.PubMedCrossRef
15.
Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Glioti G, A Trequattrini, Palumbo R. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalagia. 1995;15(5):384–390.
16.
Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999;76(2–3):176–83.PubMedCrossRef
17.
Eftekhari S, Salvatore CA, Calamri A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–96.PubMedCrossRef
18.
19.
de Prado BM, Russo AF. CGRP receptor antagonists: a new frontier of anti-migraine medications. Drug Discov Today Ther Strateg. 2006;3(4):593–7.PubMedPubMedCentralCrossRef
20.
Wang X, Han C, Fiscus RR. Calcitonin gene-related peptide (CGRP) causes endothelium-dependent cyclic AMP, cyclic GMP and vasorelaxant responses in rat abdominal aorta. Neuropeptides. 1991;20(2):115–24.PubMedCrossRef
21.
Durham PL. CGRP receptor antagonists – a fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073–4.PubMedCrossRef
22.
Durham PL. Emerging neural theories of migraine pathogenesis: calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(Supplement 1):S3–8.PubMedPubMedCentralCrossRef
23.
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–1110.
24.
Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP- antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25(2):139–47.PubMedCrossRef
25.
Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230–44.PubMedCrossRef
26.
Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304–12.PubMedCrossRef
27.
Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958–66.PubMedCrossRef
28.
Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, Mannix LK, van Oosterhout WPJ, Koppenhaver J, Lines C, Ferrari MD, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia. 2016;36(2):148–61.PubMedCrossRef
29.
Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58(Supplement 3):238–75.PubMedCrossRef
30.
Ubrelvy [package insert]. Madison, NJ: Allergan USA, Inc.;2019.
31.
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019;5;381(23):2230–2241.
32.
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;19;322(19):1887–1898. Erratum in: JAMA. 2020;323(13):1318.
33.
Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M, Yu SY, Finnegan M, Severt L, Trugman JM. Long-Term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020; 60(1):141–152. Erratum in: Headache. 2021;61(6):978–981.
34.
Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021;41(9):979–90.PubMedCrossRef
35.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9.PubMedCrossRef
36.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–45.PubMedCrossRef
37.
Johnston K, Harris L, Powell L, Popoff E, Coric V, L ’Italien G, Schreiber CP. Monthly migraine days, tablet utilization, and quality of life associated with rimegepant – post hoc results from an open label safety study (BHV3000–201). The Journal of Headache and Pain. 2022; 23(1):10.
38.
• Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM. Ubrogepant for the acute treatment of migraine when administered during the prodrome (premonitory phase): results from a phase 3, randomized, double-blind, placebo-controlled, crossover study. Presented at AAN Annual Meeting; April 22–27; Boston, MA. Abstract 2023;S47.001. The PRODROME study reportedly demonstrated the effectiveness of ubrogepant in treating the prodromal phase of a headache. The findings of this study could hold significant implications on future research on other gepants for a similar purpose and the use of gepants in treating the prodromal phase in a clinical setting.
39.
Schwedt TJ, Lipton RB, Goadsby PJ, Chiang C-C, Klein B, Liu C, Yu SY, Severt L, Finnegan M, Trugman JM. Characterizing prodrome (premonitory phase) in migraine: results from the PRODROME trial screening period. Presented at AAN Annual Meeting; April 22–27; Boston, MA. Abstract 2023;S41.009.
40.
Goadsby PJ, Ailani J, Dodick DW, Starling AJ, Liu C, Yu SY, Brand-Schieber E, Finnegan M, Trugman JM. Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): results from the PRODROME Trial. Presented at AAN Annual Meeting; April 22–27; Boston, MA. Abstract 2023;S47.002.
41.
Lipton RB, Harriott A, Ma J, Smith JH, Severt L, Strokes J, Gandhi P, Parikh K, JM Trugman, Dodick DW. Improvement in patient-reported outcomes when ubrogepant is administered during the migraine prodrome (premonitory phase): results from the PRODROME Trial. Presented at AAN Annual Meeting; April 22–27; Boston, MA. Abstract 2023;P9.001.
42.
Bertz R, Donohue MK, Madonia J, Bhardwaj R, Stringfellow J, Anderson M, Stock DA, Morris BA, Coric V, Croop R. Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults [abstract no. P-142]. Headache 2022;62:122.
43.
Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153–63.PubMedPubMedCentralCrossRef
44.
•• Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–217. Erratum in: Lancet Neurol. 2023;22(5):e7. The FDA approval of zavegepant in March 2023 was a direct result of this phase 3 study. It is the first gepant to be available in nasal spray form, and the results indicate that it can provide pain relief in as little as 15 min.
45.
46.
Nurtec [package insert]. New Haven, CT: Biohaven Pharmaceuticals, Inc.; 2020.
47.
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomized, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60.PubMedCrossRef
48.
Baker TE, Croop R, Kamen L, Price P, Stock DA, Ivans A, Bhardwaj R, Anderson MS, Madonia J, Stringfellow J, Bertz R, Coric V, Hale TW. Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeed Med. 2022;17(3):277–82.PubMedPubMedCentralCrossRef
49.
50.
Qulipta [package insert]. North Chicago, IL: AbbVie Inc.; 2021.
51.
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomized phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–37.PubMedCrossRef
52.
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM. ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.
53.
•• Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3–11. This paper provides additional analysis on the ADVANCE study that led to the approval of atogepant for preventive treatment of episodic migraine. The analysis shows that preventive efficacy was evident as early as the first day following the first dose, with a statistically significant reduction in weekly migraine days in the first month and a decrease in monthly migraine days each month.
54.
Dodick DW, Hay DL, Walker CS, Goadsby PJ, Ailani J, Severt L, Finnegan M, Ma J, Guo H, Trugman JM. Decrease in body weight with once-daily atogepant for the preventive treatment of migraine: a post hoc analysis. Headache. 2022;62(Supplement 1):96–7.
55.
Blumenfeld A, Hutchinson S, Pavlovic J, Best P, Monteith T, Ma J, Smith JH, Severt L, Dabruzzo B, Nahas S. Post-hoc analysis of safety in phase 3 atogepant ADVANCE trial participants with or without cardiovascular disease risk factors. Neurology. 2022;98(18 Supplement):1583.
56.
Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L, Periclou A. A single supratherapeutic dose of atogepant does not affect cardiac repolarization in healthy adults: results from a randomized, single-dose, phase 1 crossover trial. Clin Pharmacol Drug Dev. 2021;10(9):1099–107.PubMedPubMedCentralCrossRef
57.
Min KC, Kraft WK, Bondiskey P, Colón-González F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf M, Matthews C, Boinpally R. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. Clin Transl Sci. 2021;14(2):599–605.PubMedCrossRef
58.
59.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby P, Lipton R, Reuter U, Guo H, Schwefel B, Boinpally R, McCusker E, Yu SY, Finnegan M, Trugman J. Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial. Presented at AAN Annual Meeting; April 22–27; Boston, MA. Abstract 2023;S47.005.
60.
Best P, Harriott A, Monteith T, Tassorelli C, Nahas S, Liu Y, Dabruzzo B, De Abreu Ferreira R, Smith JH. Post Hoc Analysis of PROGRESS: evaluating the safety of atogepant in participants with chronic migraine and cardiovascular risk factors. Presented at AAN Annual Meeting; April 22–27; Boston, MA. Abstract 2023;P10.012.
61.
Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734–42.PubMedPubMedCentralCrossRef
62.
Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642–52.PubMedPubMedCentralCrossRef
63.
Bedrin K, Ailani J, Dougherty C. Raynaud’s phenomenon associated with calcitonin gene-related peptide receptor antagonists case report. Headache. 2022;62(10):1419–23.PubMedCrossRef
64.
Breen ID, Brumfield CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L, Pittelkow MR, Mangold AR. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open. 2021;4(4): e217934.PubMedPubMedCentralCrossRef
65.
Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet. 1993;342(8863):80–3.PubMedCrossRef
66.
Gérard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Michel Lantéri-Minet M, Drici M-D. Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. 2022;23(1):53.PubMedPubMedCentralCrossRef
67.
Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445–58.PubMedCrossRef
68.
Metadaten
Titel
A Brief Review of Gepants
verfasst von
Diana Li
Jessica Abreu
Stewart J. Tepper
Publikationsdatum
02.08.2023
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 9/2023
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-023-01142-1

Weitere Artikel der Ausgabe 9/2023

Current Pain and Headache Reports 9/2023 Zur Ausgabe

Episodic Migraine (S Parikh, Section Editor)

Episodic Migraine and Psychiatric Comorbidity: A Narrative Review of the Literature

Acute Pain Medicine (R Urman, Section Editor)

Postoperative Rebound Pain: Our Current Understanding About the Role of Regional Anesthesia and Multimodal Approaches in Prevention and Treatment

Secondary Headache (M Robbins, Section Editor)

Telemedicine in Headache Medicine: A Narrative Review

Acute Pain Medicine (R Urman, Section Editor)

The Acute Perioperative Pain Service: Impact, Organization, and Future Directions

Acute Pain Medicine (R Urman, Section Editor)

Acute Pain and Development of Opioid Use Disorder: Patient Risk Factors

Acute Pain Medicine (R Urman, Section Editor)

Addressing Bias in Acute Postoperative Pain Management

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Blutdrucksenkung schon im Rettungswagen bei akutem Schlaganfall?

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise